Covant Therapeutics proclaims expertise in chemistry, proteomics, and deep learning, leveraged in developing covalent therapeutics. Co-founder Ben Ruprecht has over 10 years of expertise in spectrometry-based proteomics and chemoproteomics, acting as head of the Proteomics Platform at Covant.

Covant Therapeutics

Rotational Analyst

Entrepreneur-in-Residence, Value-Based Care, Roivant Health

Associate, Governance

Principal, Roivant Health

Associate, Roivant Health


                Orally Bioavailable and Site-Selective Covalent STING Inhibitor Derived from a Macrocyclic Marine Diterpenoid
              

On behalf of the whole Covant Therapeutics team, thank you Tudor Oprea, MD PhD!

Boehringer puts $481M on the line to pursue emerging cancer target in Covant team-up - Fierce Biotech

        
            
                                    Featured • Mar 29, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                            
                    
            
            
                
                    
                          Forbes: Deals of the Week

                    
                
            
            
                
                    
                        
                    
                    
                        2023
                    
                
            
        
    

                
                        
                                                    Covant Therapeutics announced an exclusive collaboration with Boehringer Ingelheim.
                                Forbes
            
        
    

Congratulations on your well-deserved promotions Liz Brady, Christopher Dawson, and Keith P. Moore!

 Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients 

        
            
                                    News • Mar 7, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                        
                                                              Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

                                                                        “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs”
                                Iván Cornella, PhD
            
        
    

Our Covant Therapeutics DMPK team, lead by Dr. Lucinda R. Hittle, braves the winter Boston cold (hopefully in its last season days) to enjoy live discussion forums. Late winter frostbite will not deter us from enjoying in-person #drugdiscovery discussions!

PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board - Cambridge Network

        
            
                                    Featured • Mar 28, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                            
                                                            

                          

    
    
                
                        
                                                              March 28, 2023: Partnership Announced with Boehringer Ingelheim 

                                                                        Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
                                Covant Therapeutics
            
        
    

Covant Therapeutics - The Pharma Letter

        
            
                                    News • Mar 29, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                            
                                                            

                            
                  
              
              
              
              
              
              
              
              
              
              
              
                  

  

    
    
                
                        
                                                              Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1

                                                                        Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1 (adenosine deaminase acting on RNA).
                                Biospace
            
        
    

On behalf of the whole team, congratulations Christine Kaiser on receiving Covant Catalyst award, for demonstrating our team #CoreValues in practice!
#science #leadership

        
            
                                    News • Mar 29, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                        
                                                              Covant and Boehringer link up to create ADAR1 inhibitor for cancer patients

                                                                        The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients.
                                The Pharma Letter
            
        
    

As Covant Therapeutics continues to advance its Immunology & Inflammation portfolio, we are excited to grow the team welcoming our new Head of DMPK, Dr. Lucinda R. Hittle. 
Lucinda brings critical expertise and knowledge to strengthen our preclinical strategy and augment our capabilities.
#drugdiscovery #preclinical #dmpk #covalency

At Covant Therapeutics we are excited to showcase our innovative capabilities and approach to target enablement and drug discovery. 
If you are in town next week attending Discovery & Development by Oxford Global US 2024, please stop by to hear and chat with our CSO and co-founder, Ivan Cornella-Taracido, about how we are reducing new ideas in covalency to practice to advance new therapeutics.

#OGDiscoveryUS24 #DiscoveryUS #DiscoveryUS24 #drugdiscovery #covalency


                Advancing Covalent Ligand and Drug Discovery beyond Cysteine
              

Join the event to hear the latest on Covant Therapeutics mission and vision to create better drugs through covalency from Ivan Cornella-Taracido and Jamie Rice. 
#drugdiscovery #drugdevelopment #covalency

Covant bonds with Boehringer in $481M covalency-driven oncology deal - BioWorld MedTech

Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 - BioSpace

Coming back even more energized from a phenomenal meeting on the expansion of covalent therapeutics organized by the British Pharmacological Society, hosted at AstraZeneca.
It is invigorating and exciting to see how this research field and community continues to expand the repertoire of mechanisms of action (MoAs) to develop new medicines for patients in need.
The diversity of topics and speakers, with top academics such as (in a.o.) Brad L. Pentelute, Daniel Nomura, David Mann, Lyn Jones, and Nir London, young raising stars like Megan Matthews, Peter Cossar in academia, and Andrea Gohlke and Emma Grant in pharma (plus all those that presented their posters!), as well as established biotech and pharma professionals, packed in two days many lessons learned and forward thinking to continue to expand the reach of covalency in pharmaceutical research. 
My colleagues at Covant Therapeutics and I believe that covalent drug discovery is poised to grow, beyond molecular weight limits (e.g. peptides), beyond current target classes and subcell compartments (e.g. transcriptional machinery, the membranome), beyond single reactive amino acids (e.g. Lys, Tyr, His), beyond irreversibility (e.g. new chemistries), beyond oncology (e.g. I&I), and even further when efficiently combined with other modalities (e.g. glues). 
Wholehearted thanks to the organizing committee (kudos in a.o. to Bharath Srinivasan, Mark, S. B McAlister, Sarah Hewitt and Simon Lucas), the BPS staff (shoutout to Bonnie Rayner and Mariam Chahid), the session chairs, and the generous science sponsors that augment our own capabilities with their expertise (also in a.o. Applied Photophysics, Enzymlogic, Fida Biosystems, Genedata, OmicScouts, Pelago Bioscience AB, Promega Corporation , Selvita, and WuXi AppTec), without forgetting the Royal Society of Chemistry.
#drugdiscovery #covalency

 Matt LaMarche on LinkedIn: Identification of Selective Imidazopyridine CSF1R Inhibitors 

Roivant’s Covant Therapeutics and BI join forces to explore covalent drug space - MM+M Online

        
            
                                    News • Mar 28, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                        
                                                              With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders

                                                                        Roivant Sciences has added another branch to its family tree, unveiling Covant Therapeutics with a $10 million upfront commitment from Boehringer Ingelheim to turn up the heat in cancer.
                                Endpoints News
            
        
    

 Covant Therapeutics on LinkedIn: Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An… 

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement - Yahoo Finance

        
            
                                    News • Mar 29, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                        
                                                              Covant bonds with Boehringer in $481M covalency-driven oncology deal

                                                                        Boehringer Ingelheim GmbH has agreed to pay Covant Therapeutics Inc. $10 million for exclusive rights to the latter’s ADAR1-targeting immuno-oncology program.
                                BioWorld
            
        
    

Proteomic Based Drug Discovery Summit 2025 - Pharmaphorum

Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer - GlobeNewswire

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech - Fierce Biotech

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders - Endpoints News

 Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer 

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m - PMLiVE

 Roivant’s Covant Therapeutics and BI join forces to explore covalent drug space 

If you are attending Hanson Wade’s Proteomics in Drug Discovery Summit, check out the workshop and talk of Jagat Adhikari, our Head of Structural Proteomics. Jagat will share insights and examples on how we use #DeepLearning to augment data acquisition and interpretation for both discovery (“bottom up”) and structural proteomics to enable target prosecution and lead finding.
#DrugDiscovery #Proteomics

        
            
                                    News • Mar 29, 2023                            
            
                
                    
                    
                    
                
            
        
                        
                        
                                                              Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

                                                                        The deal to develop a small-molecule inhibitor could be worth over $480m
                                PM Live
            
        
    

Thank you Kerry Holtham and Hanson Wade Group for organizing the second Covalent Drug Discovery & Development Summit.
On behalf of all my colleagues at Covant Therapeutics, it will be an honor to chair an event with a remarkable panel of subject matter experts from industry and academia.

Explore the program here: https://ter.li/bgq1f
#drugdiscovery #covalency


                Morita–Baylis–Hillman Adduct Chemistry as a Tool for the Design of Lysine-Targeted Covalent Ligands
              

Phenomenal work by the teams of Ben Cravatt and Michael Erb. Congratulations to all contributors!
At Covant Therapeutics we love the endorsement and evidence that covalent small molecules can enable transcriptional machinery regulation and druggability like never before. 
#drugdiscovery #covalency #targetenablement


              Emergence of irreversible modulation in drug discovery
            


                Plasma IgG Glycosylation Profiling Reveals the Biological Features of Early Chronic Obstructive Pulmonary Disease
              

Covant Therapeutics

Business:

About: